Optimed appoints Menicon as exclusive distributor for Japan and Taiwan

NewsGuard 100/100 Score

Optimed Ltd. and Menicon Co., Ltd. announced on January 26 the expansion of Optimed products into the Asia market by the appointment of Menicon as exclusive distributor for Japan and Taiwan.

Menicon will offer eye-care professionals in Asia the opportunity to grow their practices using Optimed's CAPTIV8online communication service and i-Vue WEB content driven digital signage software.

Commenting on the partnership, Dr. Trusit Dave, Director of Optimed said, "I am delighted to have a global company like Menicon to partner with in Japan and Taiwan. Menicon's strong presence in these markets will allow us to present our technology to a large base of potential users."

CAPTIV8online is a web-based 3D animation communication software that can be used chair-side to draw over video in order to upgrade and enhance communication with patients. Uniquely, this technology also enables consumers to view the content in their homes and share the content with colleagues using the well-established principles of viral marketing. CAPTIV8online also enables patients to request appointments with practices and thereby generates incoming 'leads'. 

i-Vue WEB is a commercial grade digital signage software that is powered by Optimed's 3D animations. Furthermore, i-Vue WEB enables playlists and personalised messages to be 'pushed' to many installations remotely. i-Vue WEB offers practitioners the ability to display 'live' news and weather feeds in order to present high quality information at the point of purchase.

"As people around the world increasingly adopt the use of social networking and the internet into their daily lives, Menicon sees the need and potential to harness the capabilities of i-Vue Web and CAPTIV8online to explain complex information about eye health to its target audiences," commented Mr. Toshio Matsushima, Senior Executive Officer, Menicon Company. "The idea that a picture is worth a thousand words can now be multiplied exponentially with the easy re-distribution of dynamic digital content to help patients make informed decisions about their eye health."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pitt researchers uncover mechanisms behind uveal melanoma resistance